These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 8334682

  • 1. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
    Maeda M, Asano T, Kleinerman ES.
    Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
    [Abstract] [Full Text] [Related]

  • 2. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M, Knowles RD, Kleinerman ES.
    Cancer Commun; 1991 Aug; 3(10-11):313-21. PubMed ID: 1722107
    [Abstract] [Full Text] [Related]

  • 3. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T, McWatters A, An T, Matsushima K, Kleinerman ES.
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [Abstract] [Full Text] [Related]

  • 4. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W, Griffin JR, Kleinerman ES.
    Cancer Immunol Immunother; 1993 Feb; 36(1):45-51. PubMed ID: 8422667
    [Abstract] [Full Text] [Related]

  • 5. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
    Fox LE, King RR, Shi F, Kurzman ID, MacEwen EG, Kubilis PS.
    Cancer Biother; 1994 Feb; 9(4):329-40. PubMed ID: 7719380
    [Abstract] [Full Text] [Related]

  • 6. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
    Asano T, Matsushima K, Kleinerman ES.
    Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
    [Abstract] [Full Text] [Related]

  • 7. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.
    Asano T, Fujimaki W, McWatters A, An T, Matsushima K, Kleinerman ES.
    Cancer Immunol Immunother; 1993 Nov; 37(6):408-11. PubMed ID: 8242665
    [Abstract] [Full Text] [Related]

  • 8. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T, Kleinerman ES.
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [Abstract] [Full Text] [Related]

  • 9. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
    Tandon P, Utsugi T, Sone S.
    Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N.
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [Abstract] [Full Text] [Related]

  • 11. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.
    Asano T, McIntyre BW, Bednarczyk JL, Wygant JN, Kleinerman ES.
    Oncol Res; 1995 Aug; 7(5):253-7. PubMed ID: 8534931
    [Abstract] [Full Text] [Related]

  • 12. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
    Fogler WE, Fidler IJ.
    Int J Immunopharmacol; 1987 Aug; 9(2):141-50. PubMed ID: 3583507
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Shi F, MacEwen EG, Kurzman ID.
    Cancer Res; 1993 Sep 01; 53(17):3986-91. PubMed ID: 8358727
    [Abstract] [Full Text] [Related]

  • 14. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES.
    Hematol Oncol Clin North Am; 1995 Aug 01; 9(4):927-38. PubMed ID: 7490249
    [Abstract] [Full Text] [Related]

  • 15. The schistosomulicidal activity and the production of IL-1 and TNF-alpha by peritoneal macrophages from infected mice and their potentiation by muramyl tripeptide-phosphatidyl ethanolamine (MTP-PE) treatment.
    Seger M, Gold D, Lengy J, Pauli H, Keisari Y.
    Parasite Immunol; 1993 Jun 01; 15(6):339-47. PubMed ID: 8361776
    [Abstract] [Full Text] [Related]

  • 16. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
    Dinney CP, Tanguay S, Bucana CD, Eve BY, Fidler IJ.
    J Interferon Cytokine Res; 1995 Jun 01; 15(6):585-92. PubMed ID: 7553228
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N.
    J Immunother Emphasis Tumor Immunol; 1995 Apr 01; 17(3):181-93. PubMed ID: 7613644
    [Abstract] [Full Text] [Related]

  • 18. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
    Sone S, Utsugi T, Tandon P, Ogawara M.
    Cancer Immunol Immunother; 1986 Apr 01; 22(3):191-6. PubMed ID: 3731204
    [Abstract] [Full Text] [Related]

  • 19. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
    Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, Jiskoot W, Lankester AC, Schilham MW.
    J Exp Clin Cancer Res; 2014 Mar 10; 33(1):27. PubMed ID: 24612598
    [Abstract] [Full Text] [Related]

  • 20. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES, Maeda M, Jaffe N.
    Cancer Treat Res; 1993 Mar 10; 62():101-7. PubMed ID: 8096724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.